Incidence of synchronous lung carcinomas is rare. Making a definitive diagnosis of synchronous lung carcinomas is in many cases difficult by conventional morphological pathology. Molecular analysis may be very helpful in this regard as well as for targeted therapy. Here, we present three cases with synchronous double lung cancers proved by molecular analysis. The first case was a 68-year-old woman with two separate lung masses, one in the left upper lobe and the other in the right lower lobe. The histological features of these two tumors were almost indistinguishable. KRAS mutation analysis was performed and identified a c.35G>T, p.G12V mutation in the tumor of the left upper lobe and a distinct c.35G>A, p.G12D mutation in the tumor of the left lower lobe. The second case was a 78-year-old woman. Two lung nodules were resected, both from the left lower lobe. Histologically, both were well differentiated adenocarcinoma. Molecular studies identified a missense mutation, p.L858R of the EGFR gene, in the first nodule, and two missense mutations, p.L861Q (exon 21) and p.G719A (exon 18) of the EGFR gene, in the second nodule. The third case was an 80-year-old woman with two lung nodules. They were resected separately in an interval of five months. Histologically, both tumors were adenocarcinoma with lepidic features. Molecular analysis identified a KRAS p.G12V in one nodule, but no mutations were identified in the other tumor. Without these molecular findings, it would have been difficult, if not possible, to determine whether these tumors were two independent primaries or one tumor was the metastasis from the other tumor. Thus these findings suggested that molecular analysis may be a powerful approach to demonstrating tumors' independence. Potentially, molecular analysis can also be utilized as a biomarker to track the tumors when they become recurrent or metastatic. (2014) (2015) (2016) . Clinicopathologic features including age; general diagnostic category (benign, atypia, or malignant); availability of, absolute, and approximate (≤1 hr, >1 but <4 hr, and ≥4 hr) CIT; performance of ER, PR, and/ or Her2, and missing data (excision time and/or time in formalin), were recorded. Results: Partial analysis (~50% of data) included 1,342 cases, 320 (23.9%) EB, 600 (44.7%) lumpectomy, and 422 (31.4%) mastectomy specimens. Mean age was 54.4 years (range 11-91), and 99.7% were female patients. A total of 472 (35.2%) were benign, 93 (6.9%) atypia, and 777 (57.9%) malignant. Malignant diagnoses were more frequent for lumpectomy (509/600; 84.8%) vs mastectomy (223/422; 52.8%) and EB (44/320; 13.8%). CIT was available for 84.4%, most frequently for mastectomy (385/422; 91.2%) vs lumpectomy (526/600; 87.7%) and EB (221/320; 69.1%). CIT was ≤1 hr and ≤4 hr for 872/1,132 (77.0%) and 1,118/1,132 (98.8%), respectively. ER, PR, and/or Her2 were performed in 265 (19.7%), most frequently for Her2 alone (146/265; 55.1%) and on lumpectomies (156/265; 58.9%). Of 210 cases without CIT, excision time and time in formalin were missing for 111 (52.9%) and 167 (79.5%), respectively. Conclusions: Our rapid triage protocol allows for optimal CIT for the majority of breast resections; this is of growing importance as ancillary studies are increasingly recommended to be performed on these specimens.
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Hyperglycemia Alters T-Cell Priming by Dendritic Cells
Nadine Lerret, PhD, Naomi Iwai, MS, Amanda Marzo, PhD, Douglas Kuperman, PhD; Rush University, Chicago, IL Introduction: Inflammation and hyperglycemia are thought to play leading roles in the progression from prediabetes to type 2 diabetes; however, the exact immune mechanisms underlying the rapidly progressing pathogenesis of this disease are unclear. One recent study showed hyperglycemia induces a proinflammatory cytokine profile in human dendritic cells (DCs), leading to their maturation. What effect this has on the T-cells that the dendritic cells subsequently encounter in hyperglycemic conditions
